Testing two pills vs one for pulmonary hypertension with heart or metabolism issues
Treatments studied
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with PAH within the past 6 months and not have taken any PAH medicines before.
- You must have at least two of the following: high blood pressure, diabetes, obesity (BMI 30 or higher), or coronary heart disease.
- Your heart catheterization must show certain pressure readings (e.g., average pulmonary artery pressure at least 25 mmHg).
- You cannot have other types of lung or heart problems, severe kidney or liver disease, or be pregnant or breastfeeding.
- You must be willing to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This trial tests a medicine called ambrisentan for people with early, low-risk pulmonary arterial hypertension. The goal is to see if starting treatment early can help manage the condition before it gets worse.
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.